Systematic search for novel treatments of infantile spasms among sigma-1 receptor ligands

系统性寻找 sigma-1 受体配体治疗婴儿痉挛症的新方法

• 批准号: 10216455
• 负责人: LIBOR VELISEK
• 金额: $ 45.1万
• 依托单位: NEW YORK MEDICAL COLLEGE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-01 至 2023-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10216455
• 关键词: Acute; Adrenal Cortex Hormones; Adverse effects; Age; Age-Months; Animal Model; Attention; Behavioral; Betamethasone; Cardiomyopathies; Child; Childhood; Clinical Trials; Cognitive; Corticotropin; Cushingoid habitus; Development; Developmental Delay Disorders; Disease; Electrolytes; Epilepsy; FDA approved; Family; Gastric ulcer; Growth; Hormonal; Human; Hypertension; Hypsarrhythmia; Immunosuppression; Impairment; Infantile spasms; Intractable Epilepsy; Laboratories; Lesion; Ligands; Live Birth; Medical; Modeling; Morbidity - disease rate; N-Methylaspartate; Neurodevelopmental Deficit; Newly Diagnosed; Obesity; Outcome; Patients; Peripheral; Pharmaceutical Preparations; Phase; Pituitary-Adrenal System; Preclinical Testing; Predictive Value; Procedures; Prognosis; Randomized; Rattus; Refractory; Retinal Diseases; Risk; Rodent Model; Scotoma; Seizures; Spasm; Syndrome; System; Testing; Treatment Efficacy; Ulcer; United States National Institutes of Health; Validation; Vigabatrin; Visual Fields; age related; aggressive therapy; behavioral study; cerebral atrophy; comparative efficacy; cost; drug candidate; effective therapy; efficacy evaluation; experience; experimental study; improved; infancy; male; mortality; novel; positive allosteric modulator; postnatal; postnatal development; postnatal period; pre-clinical; prednisolone; prenatal; prospective; randomized trial; response; side effect; sigma receptors; sigma-1 receptor; standard care; symptomatology; tool; white matter

Every year in the US ~1700 children are newly diagnosed with epileptic spasms during infancy (infantile spasms; IS). IS develop between 3-12 months of age with a predominance (60%) in males. IS are associated with significant mortality and morbidity. Medical treatment options for IS are different than for any other types of epilepsy. There are two drugs with a reasonable evidence of efficacy, both approved by FDA: ACTH (adrenocorticotropin) and vigabatrin, eliminating spasms in 50-55% of patients in long term. However, ACTH carries enormous cost burden and, in up to 43% of cases has significant and serious adverse effects, which include obesity, arterial hypertension, electrolyte imbalance, gastric ulcer, growth retardation, cardiomyopathy, and immunosuppression as well as brain atrophy. Vigabatrin is almost as effective as ACTH short-term but it lags in effects after one year. Vigabatrin has a significant risk for concentric visual field deficits due to peripheral retinopathy, which develops in an unpredictable manner. Despite the treatments, up to 85% of patients with IS have developmental regression and 67% suffer from intractable epilepsy later. We identified the following gaps: There is no systematic rigorous approach in the preclinical search for novel IS treatments. Current treatments of IS (even if in combination) are insufficient and may have serious adverse effects. Most of the developed models of IS lack validation using the ACTH efficacy. Sigma-1 receptor ligands have not been examined for efficacy against IS. Our proposal uses a validated rat model of IS consisting of prenatal priming and postnatal trigger of spasms during developmentally appropriate period. The spasms in our model are sensitive to treatment with ACTH as well as vigabatrin. There is good ictal and interictal EEG correlate of this model with IS. There are also delayed spasms or seizures with delayed EEG epileptiform activity. The model, including ACTH efficacy, has been used and reproduced in independent laboratories. In this proposal we will initiate systematic search for compounds potentially effective against IS. Our preliminary studies show that sigma receptor ligands (sigma-1 receptor allosteric modulators) have robust effects against the spasms in our model. Therefore, this class of compounds may produce novel targets for IS treatment. Our proposal will test the treatment candidates among sigma receptor ligands in the three-tier system. In Tier 1, all potential treatment compounds will be tested against the expression of spasms in the randomized prospective trial. In Tier 2, those drugs with >50% efficacy will be forwarded to the EEG study investigating their effects on both acute and delayed EEG changes. Tier 3 will investigate cognitive improvements as well as rule out behavioral adverse effects afforded by the candidate drugs successful in Tiers 1 and 2. Specific aim is to determine efficacy of sigma receptor ligands against the spasms in prenatally primed rats in three tiers. The proposal will take advantage of unique features of our rodent model of IS and deliver at least one prospective treatment candidate with efficacy comparable to or better than ACTH and with fewer adverse effects for an IND study.

在美国，每年约有1700名儿童在婴儿期被新诊断为癫痫性痉挛

项目成果

Astrocyte and Neuronal Panx1 Support Long-Term Reference Memory in Mice.

• DOI: 10.1177/17590914231184712
• 发表时间: 2023-01
• 期刊: ASN NEURO
• 影响因子: 4.7
• 作者: Obot, Price;Subah, Galadu;Schonwald, Antonia;Pan, Jian;Velisek, Libor;Veliskova, Jana;Stanton, Patric K.;Scemes, Eliana
• 通讯作者: Scemes, Eliana